stockrow
Friday 6 November 2026
Export MRVI’s income statement to Excel — free account
Maravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.
- Revenue
- +10.1%
- EPS
- +50.0%
- Free cash flow
- +123.9%
- Total debt
- −45.4%
Quarter to September 2026, against a year earlier
7.52
0.54
+7.74%
Follow MRVI
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 3 | 2 |
+8 more TTM periods Free account |
| (17.01%) | (18.79%) | (23.25%) | (27.53%) | ||
| (9.06%) | (10.31%) | (12.50%) | (14.70%) | ||
ROIC |
(13.62%) | (15.83%) | (22.18%) | (28.16%) | |
Return on Tangible Assets |
(25.59%) | (29.80%) | (29.37%) | (32.46%) | |
Average Days of Receivables |
44.06 | 54.44 | 59.57 | 50.11 | |
Free Cash Flow per Share |
(0.08) | (0.24) | (0.36) | (0.49) | |
Free Cash Flow |
(12.54) | (35.84) | (52.60) | (70.72) | |
Capital Expenditures |
(7.44) | (10.58) | (13.08) | (13.15) | |
| Other line items | |||||
Cash ROIC |
(2.13%) | (5.95%) | (6.53%) | (7.76%) | |
Accounts Receivable Turnover |
8.83 | 7.07 | 6.61 | 5.80 | |
Accounts Payable Turnover |
17.90 | 14.58 | 16.03 | 20.41 | |
Inventory Turnover |
2.93 | 3.09 | 3.21 | 3.35 | |
Average Days of Payables |
18.26 | 19.13 | 21.52 | 7.00 | |
Days of Inventory on Hand |
121.79 | 110.71 | 102.02 | 97.40 | |
Tax Rate |
0.00 | 0.00 | (0.02) | (0.02) | |
Research and Development Expense of Revenue |
6.93% | 7.29% | 8.01% | 9.37% | |
Selling, General and Administrative Expense of Revenue |
57.80% | 61.31% | 65.77% | 78.13% | |
Share Based Compensation of Revenue |
14.55% | 14.34% | 12.95% | 16.25% | |
Interest Coverage |
(4.57) | (4.89) | (6.48) | (7.98) | |
Operating CF/Net income |
0.08 | 0.33 | 0.38 | 0.44 | |
Depreciation/Fixed assets |
0.00 | 0.41 | 0.41 | 0.41 | |
Capex/Depreciation |
0.00 | (0.18) | (0.22) | (0.21) | |
Revenue per Share |
1.43 | 1.41 | 1.40 | 1.29 | |
Operating CF per Share |
(0.03) | (0.17) | (0.27) | (0.40) | |
Capex per Share |
(0.05) | (0.07) | (0.09) | (0.09) | |
Capex to Sales |
0.03 | 0.05 | 0.06 | 0.07 |
Columns are period end dates · fundamentals updated 5 Nov 2026